Top Biotech Companies (22)
Don't see your company?
Create a company profile
Vulcan Augmetics is building a distribution and data ecosystem for the $156BN biosignal sensor market. Using ML powered wireless EMG sensors with deep learning networks, our goal is to become the gateway between hardware and humanity, providing high fidelity biodata and feedback so that healthcare professionals can make better decisions for their patients, and everyday users can control their devices with their body. We have launched this technology with the worlds most affordable robotic prosthetic hand and fastest-adapting ML powered wireless sensor system
Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and development efforts. This cutting-edge platform empowers us to swiftly explore numerous linker and payload combinations alongside our proprietary antibodies. We further harness state-of-the-art technologies, including an exclusive payload library derived from an FDA-approved drug and site-specific conjugation methods. These innovations are strategically employed to enhance the safety and quality of our ADCs. With two potential best-in-class programs on track for clinical trials by 2025 and a third program making headway toward IND status, we are poised for significant value creation and breakthroughs in cancer therapeutics. Based in Singapore, we plan to expand our clinical development operations to the United States by 2024. Join us on our journey to transform cancer treatment and make a meaningful impact in biotechnology. Axcynsis is at the forefront of developing life-changing ADC therapies, and we invite you to be a part of our innovative and dedicated team as we pioneer the future of cancer therapeutics.
Avant is the first cultivated fish company in Asia, with operations in Singapore and Hong Kong. Thanks to Avant's technology, we will be able to have fish meat without killing fish. Our cultivated fish products are more nutritious than conventionally produced fish, GMO-free, and pollutant-free. The pilot product focus of Avant's technology platform is fish and seafood tailored for the food culture of consumers in China and Asia.
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery
AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance
Anuva is creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies, which greatly empower drug development opportunities.
AMILI is a precision gut microbiome company based in Singapore, serving the region. Through AMILI's proprietary analytics engine, PRIME, we develop diagnostics tests, predictive algorithms and microbiome-modifying interventions. Our consumer health arm, BIO & ME, utilises insights from AMILI's database and PRIME to generate Asia-centric solutions towards personalised diet, supplementation and precision health. AMILI also houses Southeast Asia's first and only gut microbiome bank for clinical use and research. For more information, visit www.amili.asia.
Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum. We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide. Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey. MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics. Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases. We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.
We are a molecular life science company dedicated to advancing human health through innovation. By designing and building breakthrough molecular platforms that are both accessible and best-in-class, One BioMed is providing biomedical researchers and clinicians with unprecedented access to cutting-edge tools.
Founded in 2019, Virtue Diagnostics is an in vitro diagnostic provider committed to platform innovation in emerging markets. We have built a management team with decades of experience in the in vitro diagnostic industry and a global vision, coupled with robust R&D, operation and commercialization capabilities. We set up our industrialization bases in China, Brazil and Indonesia, and R&D centers in Singapore, China and Brazil. We are continuously expanding our global footprint through cooperative R&D, investment, mergers and acquisitions. Focusing on oncology and chronic diseases, Virtue Diagnostics utilizes innovative technology platforms such as clinical mass spectrometry, multiplex immunohistochemistry and molecular diagnostics to expand the China market. Through local capabilities built in emerging countries, Virtue is providing completed diagnostics menu cross biochemistry, chemiluminescence and molecular technologies.
Entobel is converting low value organic substrate into high quality products thanks to insects. Our main current products are sustainable animal feed (proteins and oils) and organic fertilizer. Since 2013, Entobel is running a commercial scale production site in Vietnam and exporting products worldwide. Entobel complies with highest standards in the industry (ISO 22000), only use tracable feedstocks and is FDA approved. Entobel is looking for strong partners to join for its expansion plans. Don't hesitate to contact us for more information.
Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.
AIM Biotech's platform and world-class lab services let drug researchers get more relevant, human-focused data at every stage of development. That means more informed decisions and less wasted time. Streamline your workflow. Rethink how you look at life sciences. It's time to add the human element. Mice, test tubes, and other conventional preclinical models don't truly represent the complexities of the human body. Ninety percent of potential new drugs fail in humans because of the limited insight and misleading data generated in most preclinical drug studies. AIM's plug-and-play 3D cell culture systems change all of that: by enabling the equipment you already use in your lab to mimic the human microenvironment, your research project can get more predictive data at every stage. Make more informed decisions, save time, save resources. And to help you manage it, we also offer contract research services with the prestigious Institute of Molecular and Cell Biology—so you can benefit from our unique, human-focused approach to research in a world-class laboratory.
Respiree© is a digital therapeutics company providing personalized healthcare services for chronic cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. The iRIS platform by Respiree© uses data captured from remote-patient-monitors, mobile applications and medical records to longitudinally measure, track disease progression and create reports for physicians and hospitals.
We are a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Our technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Our programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.
NalaGenetics was built with the passion to make preventive, DNA-based precision healthcare accessible to as many people as possible. Specifically, catalyzed by the founders’ personal experiences of problematic medication side effects and knowledge of what genetic testing can offer, NalaGenetics aims to help people achieve better nutrition and prescription medication outcomes by analyzing their unique DNA. Today, NalaGenetics’ solutions are trusted by a growing number of healthcare providers, laboratories, insurers, and corporates in Asia and Europe. We have also won government grants and mandates to carry out genomic research projects from the Government of Singapore and others. These achievements reflect the company’s exceptional standards and depth of research as a scientist-led company, along with a commitment to delivering best-in-class genomic solutions. Find out more about us at www.nalagenetics.com
X-ZELL is an award-winning medical technology start-up specialising in next-generation cytology. Cytology – or cytopathology – is the science of diagnosing diseases by examining single atypical cells or cell clusters. X-ZELL has developed a plug-and-play solution for the detection, visualization and digitization of these phenomena in minimally invasive body liquids. Slotting seamlessly into clinical routine, it does not require complex specimen preparation and reduces the average time from sample to diagnosis from 48h to less than 4h. The result: better diagnostics and improved patient care. X-ZELL is headquartered in Singapore and has regional offices in Germany (Europe), Thailand (Southeast Asia) and the US (North America).
ProfilePrint is an A.I.-driven predictive and prescriptive profiler, providing users with accessible, affordable, and portable solutions to ascertain and predict quality and profile of a food ingredient at the point of use, within seconds. Today, an enormous amount of resources are required to physically grade food samples across multiple stages of the global supply chain. ProfilePrint’s solution redefines transaction standards, and offers sellers and buyers an unbiased reference point, expediting existing quality assessment processes – from the farm all the way to end-buyers. Our headquarter is in Singapore with sales offices in Belgium, Japan and China. Founded in 2017, ProfilePrint is funded by international venture funds, Singapore government and strategic investors including Cargill, Louis Dreyfus, Olam, Sucafina and Sinar Mas. Our solution is deployed in over 26 cities globally across five continents (North America, Latin America, Africa, Europe and Asia).
Qritive makes cancer diagnosis fast, cheap, and accurate. Qritive develops AI-powered solutions that enable histopathologic diagnosisof cancer at scale. Our clinical-decision support system for pathologists unlocks efficiency and quality gain in diagnosis, which results in better patient outcome. It includes AI Modules, an Image Management System platform (Pantheon), and a network of pathologists on-demand for services (annotations, 2nd opinion...) Our digital pathology platform has been used by several healthcare institutions in Singapore, India, Morocco, UAE, and USA, and the results have been presented at various events and journals: USCAP 2023 (deep learning on prostate biopsies), 2022 (Ki-67 on Sarcomas), and 2021 (colorectal malignancies), or Nature Scientific Report.
Work Your Passion. Live Your Purpose.
